OncoMatch/Clinical Trials/NCT06392295
PSMA-Directed Para-Aortic Radiation Therapy for Oligorecurrent Prostate Cancer
Is NCT06392295 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies multiple treatments including Androgen Deprivation Therapy and Androgen Receptor Signaling Inhibitor for prostate cancer.
Treatment: Androgen Deprivation Therapy · Androgen Receptor Signaling Inhibitor — The purpose of this prostate cancer research study is to learn about: 1. Improving control of prostate cancer using radiation therapy, delivered to the para-aortic and pelvic lymph nodes, in addition to systemic androgen suppression therapy; 2. Preserving quality of life after radiation therapy; 3. Leveraging imaging results from prostate-specific membrane antigen (PSMA) positron emission tomography (PET)/computed tomography (CT) scans to evaluate and manage disease progression.
Check if I qualifyExtracted eligibility criteria
Cancer type
Prostate Cancer
Biomarker criteria
Required: FOLH1 PSMA PET/CT scan positive lesion (SUV > liver uptake and CT correlate)
No more than a total of 5 lesions on PSMA PET/CT scan (each lesion defined as positive with standardized uptake value (SUV) > liver uptake and CT scan correlate)
Disease stage
Metastatic disease required
Oligorecurrent disease limited to the sub-diaphragmatic region with or without pelvic lymph nodes
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Prior therapy
Must have received: radiation therapy — pelvic/prostate
Prior pelvic radiation with disease response
Cannot have received: radiation therapy
History of prior radiation therapy outside the pelvis for prostate cancer
Cannot have received: androgen deprivation therapy
Androgen deprivation therapy (ADT) or chemotherapy in the three months prior to staging PSMA PET/CT scan (suggesting oligoprogressive disease, rather than true oligorecurrent disease) or at time of study enrollment
Cannot have received: chemotherapy
Androgen deprivation therapy (ADT) or chemotherapy in the three months prior to staging PSMA PET/CT scan (suggesting oligoprogressive disease, rather than true oligorecurrent disease) or at time of study enrollment
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- University of Miami · Miami, Florida
Showing up to 5 US sites. See all sites on ClinicalTrials.gov →
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify